POSTER SESSIONS Journal of Thoracic Oncology

Slides:

Advertisements

Similar presentations

Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model Jiang Liu, MD, Penny C.

Advertisements

Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Prognosis of younger patients in non-small cell lung cancer

PUBLISH ONLY Journal of Thoracic Oncology

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer Martin Reck, MD, PhD, Normand Blais,

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis Ruo-Chia Tseng, PhD, Jia-Ming Chang,

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT Zhen-Yu He, San-Gang Wu, Fang Peng,

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung Cancer Mark N. Adams, PhD, Joshua T. Burgess, PhD,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.

Molecular Therapy - Nucleic Acids

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Learning More from Microarrays: Insights from Modules and Networks

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Abstracts Journal of Thoracic Oncology

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Volume 122, Issue 1, Pages (January 2002)

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients Chi Wu, MD, Huaijie Hao,

Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells Sebastian Kobold,

Volume 25, Issue 3, Pages (March 2017)

Volume 7, Issue 4, Pages (April 2005)

Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

G-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients.

Volume 7, Issue 4, Pages (April 2005)

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

ORAL SESSIONS Journal of Thoracic Oncology

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis Judit Berta, MS, Istvan Kenessey, MD, Judit Dobos, PhD, Jozsef.

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies Santosh Patnaik, MD, PhD, Reema.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PUBLISH ONLY Journal of Thoracic Oncology

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Volume 25, Issue 4, Pages (April 2017)

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma

Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3 Jiaxin Lin, Xin Tan,

MiR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1 Qi Song, Quanbo Ji, Jingbo Xiao, Fang Li, Lingxiong Wang, Yin.

Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance Xin Dong, MD, Dong Lin,

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

IL-13Rα2 expression is associated to human colon cancer progression and poor survival of patients with colorectal cancer. IL-13Rα2 expression is associated.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

POSTER SESSIONS Journal of Thoracic Oncology Journal of Thoracic Oncology Volume 10, Issue 9, Pages S407-S760 (September 2015) DOI: 10.1016/S1556-0864(16)30012-0 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A) Proportion of patients receiving systemic therapy B) Overall survival for all patients by physician. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan–Meier estimates of overall survival Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier survival curves by EZH2 nuclear expression Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Study design Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig 1 Freedom from recurrence in patients with MIP/SOL Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Table 1 Multiple Lung Cancer: Molecular Data Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Central Memory T-cells in patient pbmc's pre- and post-SAR Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival in PP population. Overall survival in the PP population of a total of 27 patients. Median overall survival was 35.5 months (95% Cl: 21.3 - 49.7 months). Overall survival at 1-, 2- and 3-years was 71.0% (95% Cl: 52.8 – 80.3%), 50.1% (95% Cl: 28.3 – 61.2 %) and 25.1% (95% Cl: 0 – 43.7%) Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Progression-free survival in PP population. Progression free survival in the PP population of a total of 27 patients. Median progression free survival was 20.8 months (95% Cl: 15.3 - 26.2 months). Overall progression-free survival at 1-, 2- and 3-years was 55.6% (95% Cl: 36.8 - 65.2%), 25.9% (95% CI: 4.5 – 36.8 %) and not reach. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Strong hyaluronan (FIA) signal at the epithelial cell-extracellular matrix interface (B) in normal lung (A), coincident with regular microvessels staining (C), absence of colocalization at confocal microscopy (D) and low signal when compared to tumoral tissue (E). High expression (>48%) of HA in squamous cell carcinoma (SqCC) (F) on cancer cells-stroma interface (G), coincident with high microvessel (>33%) staining foci (H), identical colocalization at confocal microscopy (I) and higher signal when compared to normal tissue (J). HA-negative in normal lung (K) and cells of adenocarcinoma (AD) (L); note the strong HA staining in tumor stroma (L), coincident with microvessels staining (M), foci of colocalization at confocal microscopy (N) and higher expression compared to normal tissue (O). Very poor signal in normal lung (P) and in large cell carcinoma (ICC) (Q); note strong HA foci staining (Q), coincident with focal microvessels density (R), focal colocalization at confocal microscopy (S) and low signal when compared to normal tissue (T). Arrowheads indicate stromal tissue; asterisks indicate carcinoma cells. H&E; hematoxylin and eosin; MVD: microvessel density. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Comparison of Epithlioid and Biphasic cell types. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig 1 Diffuse nodular (left) and dendriform (right) pulmonary ossifications. Nodular ossifications grow within the alveolar spaces, where dendriform ossifcations branch through the septa and often contain fatty bone marrow. (H&E stain, 400x) Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Histology Incidence Trends by Race/Ethnicity Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 MFN2 regulates lung adenocareinoma cell proliferation and invasion (A) Represemative images for MFN2 expression on lung adcnocareinomations of two patients. (B) Quantification of MFN2 expression status in lung adenocarenoma adjacent normal issues. (C) Cell proliferation changes in A549 cells treated with MFN2 shRNA. (D) Cell invasion ability in A549 cells treated with MFN2 shRNA. (E) Cell cycle changes in A549 cells treated wtih MFN2 shRNA. (F) Heatmap of gene gene expression profile in A549 cells treated wtih MFN2 shRNA. (G) Funetional pathway enrichment of dercgulned gents in A549 cells treated with MFN2 shRNA. (H) Confirmation of deregulated genes in A549 cells trated with MFN2 shRNA by western blot. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) RT-PCR of ASCL1 mRNA in the disstal airways of 8 cancer-free subjects grouped according to smoking status. Difference in ASOL1 mRNA titers among me three groups did not reach statistical significance (p = 0 26) 1Data available for only one never-smoker (n=1). (B) Western blot band intensity (ASCL1/1damai B1) of A549 cels treated with cigarette smoke condensate (CSC). 1% DMSO or serum-free media (SF). A 4-hour exposure to 10 mcg/mL CSC led toa 4 1 fold increase in ASCL1 expression compared to 1% DMSO (p = 0 023) and a 2 0 fold increase compared to SF (p = 0.017). Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Involvement of MLF1IP in lung adenocarcinoma (A) Expression status of MLF1IP mRNA in lung adenocarcinoma. (B) Cell proliferation in A549 cells treated with MLFlIP shRNA by Cellomics cell counting methods. (C) Cell proliferation in A549 cells treated with MLF1IP shRNA by MTT assay. (D) Colony formation ability in A549 cells treated with MLF1IP shRNA. (E) Cell cycle status in A549 cells treated with MLF1IP shRNA. (F) Cell apoptosis in A549 cells treated with MLF1IP shRNA Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Percentage of screening participants for whom re-assignment of lung cancer risk score category occurred when their individualised SNP genotype data (genetic risk score) was added to the clinical data to derive the overall risk category. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 miRNAs expression differences. A. Comparison of miRNAs expression in patients with different stages of NSCLC and SCLC as well as in healthy individuals. B. Expression of miR-944 and miR-3662 in early stages of NSLC and in healthy control. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 ROC analysis of studied miRNAs in NSCI.C patients and their diagnostic accuracy: A - ROC for combination analysis of both miRNAs for distiagulshing early stages of NSCLC from healths control, B - ROC for analysis of miR-944 for distinguishing early stages of SCC from healthy control, C - ROC for analysis of miR-3662 for distinguish early stages AC from healthy control. Diagnostic power of analysis was shown as an AUC calculation as well as sensitivity and specificity of each ROC curves. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival in small cell lung cancer patients with NLR ≥4 versus NLR <4 (log-rank P=0.014) Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier Survival Curves Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Adenocarcinoma of the Lung: Survival in Months by Treatment Group Erlotinib Treatment versus Non-Erlotinib Treatment Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Fatigue Incidence and Worsen of Fatigue by Maintenance Cycle. Incidence of CTCAE grade 1/2 and grade 3/4 fatigue for overall (A) and East-Asian (B) patients in the pemetrexed and placebo treatment arms for maintenance cycles 1 through 10. Worsening of fatigue based on the patients-reported LCSS scores for overall (C) and East-Asian (0) patients in the pemetrexed and placebo treatment arms for maintenance cycles 1 through 10. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Patients demographic characteristics and propensity score-matched characteristics between two groups. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 A.0ptimal cutoff values of the TTAC by maximally selected log-rank statistics. Kaplan-Meier curve for NSCLC disease-free survival(DFS) according to interval between surgery and chemotherapy initiation. B. In all patients, there was significant difference in the DFS between patients who received adjuvant chemotherapy within 50 days and later than 50 days(P=0.005). C. In propensity score-matched pairs, DFS was not significant difference between the 2 groups(P=0.122). Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1 Treatment scheme Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Availability of EGFR test in routine practice Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier Curve. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier curve. Table 1. Subgroup analyses Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1. Two Group OPLS Clustering Analysis. VOC profile differences between CON (Other lung diseases) and Lung cancer Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2. Three Group OPLS Clustering Analysis. VOC profile differences among CON (Other lung diseases), Lung cancer and TB (Tuberculosis). Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1. Comparative analysis of overall survival curves between radiographically detected [chest radiography (CXR)] non-small cell lung cancer patients and symptom-prompted patients. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4. CK2α downregulation suppresses SCLC cell motility in the wound healing assay (magnification, ×200). Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

figure 1 the PFS and different gene type Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

figure 2 the OS and different gene type Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig 1 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig 2 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1 Kaplan-Meier curves for progression-free survival by treatment group Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2 Kaplan-Meier curves for overall survival by treatment group Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Patients demographic characteristics and propensity score-matched characteristics between two groups. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier plot for NSCLC disease-free survival (DFS) according to age. A. In all patients there was no significant difference in the DFS between younger patients (age≤6S years) and older patients(age >65 years) (P–0.951) B. In propensity score-matched pain. DFS was not significant difference between the 2 groups(P–0.731) Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan Meier survival curve for above and below median melatonin concentration. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier survival curves by EZH2 nuclear expression Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Kaplan-Meier curve of overall survival at 1 year according to CD117 expression (n=46) Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Stage shift according to screening arm (CXR vs CT) in the NLST-ACRIN substudy (N=18,714) after stratification by COPD status. Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10 Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10.1016/S1556-0864(16)30012-0) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions